GlassScriptPhysician profile
Jennifer E Smith
NPI 1811260821
$134,279.61
in general payments reported to CMS, 2019-2025
30 companies · $60K in 2025
The $60K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18K · 2022: $9,223 · 2023: $24K · 2024: $23K · 2025: $60K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $52K · Consulting Fee: $23K · Travel and Lodging: $17K · Food and Beverage: $14K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $500 · Education: $48.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $51,874.00 |
| Consulting Fee | $23,456.50 |
| Travel and Lodging | $16,948.04 |
| Food and Beverage | $13,934.95 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $500.00 |
| Education | $48.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $45,458.59 | 2021-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $42,597.42 | 2021-2025 | Vumerity, Tysabri, Tysabri |
| Genzyme Corporation | $26,842.20 | 2021-2025 | |
| Genentech USA, INC. | $5,507.26 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
| Novartis Pharmaceuticals Corporation | $3,720.73 | 2021-2025 | |
| Tg Therapeutics, INC. | $3,269.04 | 2023-2025 | |
| Medtronic, INC. | $2,170.64 | 2023 | Synchromedii |
| Amgen INC. | $1,955.73 | 2024-2025 | Uplizna |
| Celgene Corporation | $914.57 | 2023-2025 | Zeposia |
| Ani Pharmaceuticals, INC. | $367.31 | 2022-2025 | Purified Cortrophin Gel |
| Abbvie INC. | $366.35 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $160.15 | 2021-2025 | Ajovy, Austedo Xr |
| Horizon Therapeutics Plc | $135.63 | 2022 | |
| Alexion Pharmaceuticals, INC. | $122.80 | 2021-2025 | Ultomiris, Soliris |
| Janssen Pharmaceuticals, INC | $102.97 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $84.07 | 2022-2024 | Lioresal (Baclofen) |
| Axsome Therapeutics, INC. | $83.75 | 2024 | Auvelity |
| Avanir Pharmaceuticals, INC. | $64.83 | 2021-2022 | |
| Pfizer INC. | $63.24 | 2025 | |
| Vanda Pharmaceuticals INC. | $44.89 | 2025 | Ponvory |
| Otsuka America Pharmaceutical, INC. | $37.27 | 2023 | Nuedexta |
| Saol Therapeutics INC. | $30.00 | 2021 | |
| Sumitomo Pharma America, INC. | $28.38 | 2023 | Gemtesa |
| Piramal Critical Care | $24.04 | 2023 | |
| Phathom Pharmaceuticals, INC. | $23.81 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $23.76 | 2022 | |
| Cycle Pharmaceuticals INC | $22.86 | 2025 | Tascenso Odt |
| Kedrion Biopharma, INC. | $22.80 | 2024 | Gammaked, Kedrab, Koate |
| Acorda Therapeutics, INC | $18.96 | 2023 | Inbrija, Ampyra |
| Surmodics, INC. | $15.56 | 2023 | Pounce Thrombectomy, Sublime 014 Rx Pta Balloon Dilatation Catheter, Sublime Radial Access 018 Rx Pta Dilatation Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.